Extrahepatic Bile Duct Adenocarcinoma: Patients at High-Risk for Local Recurrence Treated with Surgery and Adjuvant Chemoradiation Have an Equivalent Overall Survival to Patients with Standard-Risk Treated with Surgery Alone

Simple item page
dc.contributor.authorBorghero, Yerko
dc.contributor.authorCrane, Christopher H.
dc.contributor.authorSzklaruk, Janio
dc.contributor.authorOyarzo, Mauricio
dc.contributor.authorCurley, Steven
dc.contributor.authorPisters, Peter W.
dc.contributor.authorEvans, Douglas
dc.contributor.authorAbdalla, Eddie K.
dc.contributor.authorThomas, Melanie B.
dc.contributor.authorDas, Prajnan
dc.contributor.authorWistuba, Ignacio I.
dc.contributor.authorKrishnan, Sunil
dc.contributor.authorVauthey, Jean-Nicolas
dc.date.accessioned2025-01-21T01:04:57Z
dc.date.available2025-01-21T01:04:57Z
dc.date.issued2008
dc.description.abstractBackground: Patients with resected extrahepatic bile duct adenocarcinoma who have microscopically positive resection margins and/or pathologic locoregional nodal involvement (R1pN1) have a high-risk of locoregional recurrence, and therefore, we advocate the use of adjuvant chemoradiation. To evaluate the safety and effectiveness of this treatment, we compared survival and side effects outcomes between such patients and patients with negative resection margins and pathologically negative nodes (R0pN0) who did not receive adjuvant treatment.
dc.description.abstractMethods: Between 1984 and 2005, 65 patients were treated with curative-intended resection for extrahepatic bile duct adenocarcinoma. Patients with tumors arising in the gallbladder and periampullary region were excluded. Pathology and diagnostic images were centrally reviewed. Overall survival and locoregional recurrence outcomes for patients with standard-risk R0pN0 (surgery alone, or S group, n = 23) were compared with those of patients with high locoregional recurrence risk, R1 and/or pN1 (R1pN1) status who received adjuvant chemoradiation (S-CRT group, n = 42).
dc.description.abstractResults: The median follow-up for the entire group was 31 months. Patients in the S-CRT and S groups had a similar 5-year overall survival (36% vs. 42%, P = .6) and locoregional recurrence (5-year rate: 38% vs. 37%, P = .13). In the S-CRT group, three patients (7%) experienced an acute (grade 3 or more) side effect.
dc.description.abstractConclusions: Our finding of a lack of a survival difference between the S and S-CRT groups suggests that for patients with extrahepatic bile duct adenocarcinoma at high risk for locoregional recurrence (i.e., R1 resection or pN1 disease), adjuvant chemoradiation provides an equivalent overall survival despite of these worse prognostic features.
dc.fuente.origenWOS
dc.identifier.doi10.1245/s10434-008-9998-7
dc.identifier.issn1068-9265
dc.identifier.urihttps://doi.org/10.1245/s10434-008-9998-7
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/95756
dc.identifier.wosidWOS:000260509400023
dc.issue.numero11
dc.language.isoen
dc.pagina.final3156
dc.pagina.inicio3147
dc.revistaAnnals of surgical oncology
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleExtrahepatic Bile Duct Adenocarcinoma: Patients at High-Risk for Local Recurrence Treated with Surgery and Adjuvant Chemoradiation Have an Equivalent Overall Survival to Patients with Standard-Risk Treated with Surgery Alone
dc.typeartículo
dc.volumen15
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas